Bristol/Merck Receive Pargluva "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites need for additional information on the cardiovascular safety profile for the dual PPAR diabetes therapy.
You may also be interested in...
Bristol, Merck End Pargluva Collaboration
Bristol-Myers Squibb says it will consider pursuing commercialization of muraglitazar independently.
Bristol, Merck End Pargluva Collaboration
Bristol-Myers Squibb says it will consider pursuing commercialization of muraglitazar independently.
Pargluva Development May Be Terminated By Bristol, Merck
Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.